Status: Not yet recruiting
Study of the Safety and Efficacy of Pancreatic Endocrine Cells in Adult Patients With Type 1 Diabetes
This study will evaluate the safety, efficacy and durability of SR-02 administered to the omentum of patients of Type 1 diabetes with severe recurrent hypoglycemia. The study will also help establish the optimal treatment dose. Although this study is open to patients with all HLA or blood types, immunosuppression to prevent rejection will be required in this first in human study.
Participants needed: 9
Trial details
Phase: Phase 1, Phase 2Age: 18-65Biological sex: AllType: InterventionalSponsor: SeraxisUpdated: May 12, 2026
Eligibility criteria
Adult 18 to 65 years with a clinical history of T1D [+4]
Use of anti-diabetic agent other than insulin(s) or insulin analog(s) within 3 m... [+1]